Emily Blyth

Emily Blyth

Westmead, NSW, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Journal: Blood advances
Published: June 29, 2026

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Journal: Transplantation and cellular therapy
Published: April 19, 2026

Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Journal: Transplantation and cellular therapy
Published: April 19, 2026

Immune cell subsets that predict cytomegalovirus reactivation magnitude after haematopoietic stem cell transplantation.

Immune cell subsets that predict cytomegalovirus reactivation magnitude after haematopoietic stem cell transplantation.

Journal: Blood
Published: February 13, 2026

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT.

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT.

Journal: Reviews in medical virology
Published: November 12, 2025

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients - PART 1: Risk Factors, Clinical Impact and Immune Response.

Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients - PART 1: Risk Factors, Clinical Impact and Immune Response.

Journal: Reviews in medical virology
Published: November 12, 2025

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Journal: Blood
Published: November 04, 2025

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Journal: Blood
Published: November 04, 2025

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 29, 2025

Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients.

Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients.

Journal: Blood
Published: April 04, 2025

Current developments in T-cell receptor therapy for acute myeloid leukemia.

Current developments in T-cell receptor therapy for acute myeloid leukemia.

Journal: Blood advances
Published: October 01, 2024

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Journal: American journal of hematology
Published: June 10, 2024
Showing 1-12 of 67

Last Updated: 09/26/2026